Clinical Trial Search

Primary: Improvement From Baseline in Atopic Dermatitis Severity Index (ADSI) Score at Day 8 — 8.22; 8.02; 8.13; 8.19 units on a scale

Primary: Percentage of Participants With Greater Decrease in Overall Target Plaque Severity Score (OTPSS) at Day 28 — 68.6; 5.7 percentage of participants — p=< 0.001

Primary: Change in Hemodynamic Parameters From Baseline to Week 24. — -2.0; 0; -1.0; 3.0 mmHg

Primary: Area Under the Curve for Oral Glucose Tolerance Test (oGGT) — 10.8; 11.0; 9.9; 10.6 mM h

Primary: Incidence of Overall Adverse Events — 12; 8; 11 participants

Primary: Incidence of Central Nervous System (CNS) Hemorrhagic Events — 0 CNS hemorrhagic events

Primary: Progression Free Survival at Six Months — 87 percentage of participants

Primary: Change From Baseline in the Itch Assessment Score Immediately Following Treatment — 1.93; 2.64 units on a scale — p=<0.001

Primary: Vacc-4x Effect on Viral Load Set-point — 38455.0; 40088.8; 45253.9; 47336.8 Copies/mL

Primary: Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84 — 2.03; 1.92; 1.83; 2.05 units on a scale — p=0.9381

Primary: Percentage of Participants With Lowering of Overall Target Plaque Severity Score (OTPSS) at Day 84 — 53.3; 30.0 percentage of participants — p=0.23

Primary: Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12 — -16.8; -18.1; -18.9; -18.8 Lesion count — p=0.692

Primary: Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily…

Primary: Remission of Vasculitis — 95 Percentage of participants

Primary: Antitumor Activity of SB-715992 Using Objective Response Rates (Partial and Complete Responses) — 0 participants